Arginase inhibitor CB-1158

Originator: Calithera Biosciences

Buyer: Incyte

Upfront payment: $45m

Estimated value: ~$500m

Target molecule: Arginase

Target cell: MDSC

Clinical setting: Combination with anti-PD-1 ab

Current stage: P1

Another Arginase inhibitors:

Target evaluation: fast-follow 가능?

http://www.calithera.com/wp-content/uploads/2016/01/Keystone-immunotherapy-2016-poster.final_.pdf

https://globenewswire.com/news-release/2017/01/30/911912/0/en/Incyte-and-Calithera-Biosciences-Announce-Global-Collaboration-to-Develop-and-Commercialize-CB-1158-a-First-in-class-Small-Molecule-Arginase-Inhibitor.html

 

Advertisements